AbbVie has launched Boey in Europe, a botulinum toxin formulation engineered for faster onset compared to Botox. The product represents a differentiated entry point in a market where onset speed—traditionally 3–7 days for standard toxins—has become a competitive lever, particularly among practitioners seeking to reduce patient wait time and improve treatment satisfaction.
Injectables
AbbVie Launches Boey, Rapid-Onset Toxin, in Europe
New neuromodulator formulation targets faster onset; competitive pressure on Botox pricing intensifies.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Faster onset becomes the new competitive battleground.
Boey's European launch signals AbbVie's intent to defend and expand its toxin franchise against rising competition from Galderma's Botox, Revance's Daxxify (which offers 6-month duration), and Korean generics like Nabota and Letybo. For U.S. practices, the question is timing: if Boey gains traction in Europe, FDA submission is likely. Practices should monitor onset claims carefully—faster onset does not equal longer duration, and patient expectations must be managed accordingly.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.